Pilocarpine SEPharmacological
Background: C57BL/6J
Seizure Onset20-40 min post-pilocarpine injection
Chronic EpilepsySpontaneous recurrent seizures by 2-4 weeks post-SE
Cognitive ImpactSpatial memory deficits detectable by 4-6 weeks post-SE
Test Window8-12 weeks
Systemic pilocarpine (a muscarinic agonist) induces status epilepticus after pretreatment with scopolamine methyl-bromide to block peripheral cholinergic effects. The model produces extensive bilateral hippocampal damage, mossy fiber sprouting, and granule cell dispersion closely resembling human mesial temporal sclerosis. Mortality during SE induction can be significant (20-40%) and is managed with diazepam termination at defined endpoints.
Ideal for: Studies of epileptogenesis and antiepileptogenic therapies, as the well-defined latent period between SE and chronic seizure onset provides a therapeutic intervention window. Also widely used for investigating cognitive comorbidities of temporal lobe epilepsy.
Curia G, et al. (2008). The pilocarpine model of temporal lobe epilepsy. J Neurosci Methods, 172(2), 143-157. PMID: 18550176
Pilocarpine SE Behavioral Battery
Morris Water Maze
Assesses hippocampal-dependent spatial learning and memory deficits that develop after pilocarpine-induced SE and chronic epilepsy.
View Morris Water Maze→Open Field Test
Evaluates general locomotor activity and anxiety-like behavior, both commonly altered in post-SE animals.
View Open Field Test→Fear Conditioning System
Measures contextual and cued fear memory, capturing hippocampal and amygdalar dysfunction after seizure-induced damage.
View Fear Conditioning System→Novel Object Recognition
Tests recognition memory, which is impaired in chronic epilepsy due to perirhinal and hippocampal pathology.
View Novel Object Recognition→Elevated Plus Maze
Quantifies anxiety-like behavior, a major psychiatric comorbidity in epilepsy patients and rodent epilepsy models.
View Elevated Plus Maze→PTZ KindlingPharmacological
Background: C57BL/6J
Seizure OnsetProgressive over 2-4 weeks of repeated PTZ injections
Chronic EpilepsyFully kindled state with generalized seizures after 15-20 injections
Cognitive ImpactModerate spatial memory deficits in fully kindled animals
Test Window6-8 weeks
Repeated subconvulsive doses of the GABA-A antagonist pentylenetetrazol (typically 35-40 mg/kg i.p. every 48 hours) produce progressive seizure intensification from myoclonic jerks to generalized tonic-clonic convulsions. Seizure severity is scored on the Racine scale. The kindling process reflects long-term neuroplastic changes in excitability without requiring an initial episode of status epilepticus.
Ideal for: Screening antiseizure drugs against progressively worsening seizures, studying seizure threshold changes over time, and investigating the neurobiological mechanisms of epileptogenesis without the confound of extensive brain lesions.
Shimada T, Yamagata K. (2018). Pentylenetetrazole-Induced Kindling Mouse Model. J Vis Exp, (136), 56573. PMID: 29985348
PTZ Kindling Behavioral Battery
Open Field Test
Monitors post-kindling changes in locomotion and anxiety-related behaviors in the open arena.
View Open Field Test→Elevated Plus Maze
Evaluates kindling-induced anxiety, which increases progressively with seizure severity.
View Elevated Plus Maze→Barnes Maze
Assesses spatial reference memory with lower physical demand than water-based tasks, suitable for kindled animals.
View Barnes Maze→Kainic AcidPharmacological
Background: C57BL/6J
Seizure Onset30-60 min post-injection (systemic) or minutes (intrahippocampal)
Chronic EpilepsySpontaneous hippocampal seizures by 1-3 weeks (intrahippocampal route)
Cognitive ImpactRobust spatial and contextual memory impairment by 3-4 weeks
Test Window8-12 weeks
Kainic acid, a glutamate receptor agonist with high affinity for kainate receptors enriched in hippocampal CA3, produces limbic seizures and excitotoxic neuronal death preferentially in the hippocampus. The intrahippocampal injection route produces unilateral hippocampal sclerosis closely modeling human mesial temporal lobe epilepsy with minimal extrahippocampal damage. Systemic administration yields more widespread pathology but higher mortality.
Ideal for: Investigating hippocampal circuit reorganization during epileptogenesis, testing neuroprotective strategies against excitotoxicity, and studying the relationship between hippocampal sclerosis and cognitive decline in temporal lobe epilepsy.
Ben-Ari Y, Cossart R. (2000). Kainate, a double agent that generates seizures: two decades of progress. Trends Neurosci, 23(11), 580-587. PMID: 11074268
Kainic Acid Behavioral Battery
Morris Water Maze
Gold-standard test for hippocampal spatial memory, severely impaired after kainic acid-induced hippocampal sclerosis.
View Morris Water Maze→Fear Conditioning System
Contextual fear conditioning is exquisitely sensitive to hippocampal damage caused by kainic acid excitotoxicity.
View Fear Conditioning System→Rotarod Test
Controls for motor impairment that could confound cognitive test interpretation, particularly after systemic KA.
View Rotarod Test→Open Field Test
Detects KA-induced hyperactivity and altered exploratory patterns during the chronic epilepsy phase.
View Open Field Test→Novel Object Recognition
Assesses perirhinal-dependent recognition memory, providing complementary data to hippocampal spatial tasks.
View Novel Object Recognition→6-Hz Corneal StimulationPharmacological
Background: CF-1 or C57BL/6J
Seizure OnsetImmediate upon electrical stimulation (6 Hz, 3 sec)
Chronic EpilepsyAcute seizure model only — no chronic epilepsy develops
Cognitive ImpactTransient post-ictal confusion; no lasting cognitive deficit
Test Window6-8 weeks
Low-frequency (6 Hz) corneal electrical stimulation for 3 seconds produces psychomotor seizures characterized by stun, forelimb clonus, twitching of the vibrissae, and Straub tail. At the 44 mA intensity, this model is resistant to many conventional antiseizure drugs including phenytoin, carbamazepine, and lamotrigine, making it a valuable pharmacoresistance screen. The model is acute, humane, and high-throughput.
Ideal for: Screening novel compounds against therapy-resistant seizures in a rapid, high-throughput paradigm. Particularly valued by the NIH/NINDS Epilepsy Therapy Screening Program (ETSP) as a frontline differentiation assay for drug candidates.
Barton ME, et al. (2001). Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res, 47(3), 217-227. PMID: 11738929
6-Hz Corneal Stimulation Behavioral Battery
Rotarod Test
Essential for detecting motor side effects of candidate antiseizure compounds tested in the 6-Hz paradigm.
View Rotarod Test→Open Field Test
Screens for sedation or hyperactivity side effects of drugs being evaluated for antiseizure efficacy.
View Open Field Test→Barnes Maze
Evaluates whether candidate drugs cause cognitive side effects at therapeutically effective doses.
View Barnes Maze→